Eisai has followed in the footsteps of Japanese peer Astellas by divesting assets in the dermatology area, this time through a deal with Roivant for a clinical stage atopic dermatitis therapy that it sees as no longer fitting into its strategic priorities.

CDER approves sNDAs from Bayer for Zegerid OTC powder and private label manufacturer Dexcel Pharma for omeprazole delayed release tablets to add label warnings on drug-drug interactions for methotrexate and mycophenolate mofetil.

CDER approves sNDAs from Bayer for Zegerid OTC powder and private label manufacturer Dexcel Pharma for omeprazole delayed release tablets to add label warnings on drug-drug interactions for methotrexate and mycophenolate mofetil.

Baar, Switzerland-based Fair-Med has named Oren Weininger chief executive officer. Prior to joining the privately owned firm, which aims to provide patients with quality generic medicines at affordable prices, Mr Weininger worked at Dexcel Pharma. He said, "I hope as CEO I will bring the company to international success with a quick expansion, based on my experience." Fair-Med is currently present in Europe, Australian and the MENA region.